Recombinant Anti-CD37 x Anti-CD64 Bispecific Antibody (IgG-Fv) (BSGV-117)

Recombinant Anti-CD37 x Anti-CD64 Bispecific Antibody (IgG-Fv) is formed by an Immunoglobulin G (IgG) and a fragment variable Fv region, in which the Fc of IgG is engineered by KIH. The Fv region of an anti-CD37 antibody variable domain is fused to the C terminal of an IgG of anti-CD64 antibody, or vice versa. The format retains desired characteristics of intact antibodies. This BsAb can retarget neutrophils cells to tumor cells. It is designed for the research of Non-Hodgkin's lymphoma (NHL); Diffuse large B cell lymphoma (DLBCL); Chronic lymphocytic leukemia (CLL) therapy.

Datasheet INQUIRY

Specifications

Targets

CD37 & CD64

Type

IgG-Fv

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Non-Hodgkin's lymphoma (NHL); Diffuse large B cell lymphoma (DLBCL); Chronic lymphocytic leukemia (CLL)

Targets

Target 1

CD37

Gene ID

951

UniProt ID

P11049

Alternative Names

CD37; CD37 molecule; GP52-40; TSPAN26; leukocyte antigen CD37; tspan-26; tetraspanin-26; leukocyte surface antigen CD37; cell differentiation antigen 37

Target 2

CD64

Gene ID

2209

UniProt ID

P12314

Alternative Names

FCGR1A; Fc fragment of IgG receptor Ia; CD64; FCRI; CD64A; IGFR1; Cluster of Differentiation 64; FcγRI; FCGR1B; FCGR1C; immunoglobulin G Fc receptor high affinity I; Fc gamma RI

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD37 x Anti-CD64 Bispecific Antibody (IgG-Fv) (BSGV-117). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD37 x Anti-CD64 Bispecific Antibody (IgG-Fv) (CAT#: BSGV-117)

Specifications

Targets

Customer Reviews and Q&As